Project Grant K01CA280185
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$147K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...
The National Cancer Institute (NCI) awarded a $148,568 Project Grant to The Leland Stanford Junior University (Stanford University) under the NCI's Cancer Research Manpower (CFDA 93.398) program. The grant, which runs from December 17, 2024 to July 14, 2027, supports research to integrate highly multiplexed immunofluorescence with label-free 2D hyperspectral chemical imaging to interrogate the colorectal cancer tumor-invasive front. This innovative approach aims to enhance the understanding of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,534 in funding to The Medical University of South Carolina to conduct research aimed at understanding how transient endoplasmic reticulum (ER) stress can enhance the anti-tumor function of T cells. The 5-year project, starting on December 1, 2024, will investigate the mechanisms by which ER stress-induced autophagy can improve mitochondrial function, metabolic programming, and...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...
This federal Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate the role of CD91-mediated signaling in priming T cell responses to nascent, emerging tumors. The primary awardee, the University of Pittsburgh, will develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. This research aims to advance the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $169,932 from September 2024 to July 2029 to The Trustees of Columbia University in the City of New York to advance proteomics technologies for cancer research. The award will enable the recipient's Proteomics and Macromolecular Crystallography Shared Resource to enhance its capabilities by developing innovative methodologies, including automated deep proteomic profiling for...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $571,271 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key goals of the 5-year project are to: (1) synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate to selectively deliver the...